ALPACA trial shows sustained Lp(a) reductions with lepodisiran  

In the Phase 2 ALPACA study, Lp(a) levels were reduced from baseline by 93.9% compared to placebo, from day 60 to 180, after a single dose of the investigational siRNA, lepodisiran 400 mg.¹ Sustained reductions of 53.4% were recorded with lepodisiran 400 mg at 540 days after a single dose and 74.2% at 540 days following a second dose of lepodisiran 400 mg at day 180.